Another SGLT2 Inhibitor OK'd for Heart Failure

(MedPage Today) -- FDA added a new indication to empagliflozin (Jardiance) for treating heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly announced.
The 10-mg once-daily dose of the SGLT2 inhibitor was okayed...